Novadaq to present at Piper Jaffray Healthcare Conference
Dr. Menawat's presentation is at 4:30 p.m. ET on Tuesday, November 27 andwill be webcast live from Novadaq's website at www.novadaq.com.
About Novadaq Technologies
Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medicalimaging systems and real-time image guided therapies for use in the operatingroom. Novadaq's proprietary ICG imaging systems can be used to visualize bloodvessels, nerves and the lymphatic system during a variety of surgicalprocedures. Novadaq's SPY(R) Imaging System, commercially available worldwide,enables cardiac surgeons to visually assess coronary vasculature and bypassgraft functionality during the course of heart bypass surgery. The SPY Systemis expandable to include upgrade kits for use during other surgeries such asplastic, reconstructive and organ transplant surgery allowing surgeons toevaluate blood flow and tissue and organ perfusion. In addition, SPY is idealfor use during urological procedures enabling surgeons to visualize vessels,tumors, the lymphatic system and potentially nerve bundles. Novadaq's OPTTX(R)System is aimed at the diagnosis, evaluation and treatment of wet Age-relatedMacular Degeneration (AMD) by using the same core imaging technology that isused in the SPY Imaging System. Novadaq also offers the FDA approvedPINPOINT(TM) endoscopic system for visualizing native tissue fluorescencewhich allows surgeons to differentiate between healthy and cancerous tissue inthe lung during thoracic surgery. Novadaq is also the exclusive United Statesdistributor of PLC Medical's CO(2) HEART LASER(TM) System for TMR(Trans-Myocardial Revascularization). For more information, please visit thecompany's website at www.novadaq.com.
Certain statements included in this press release may be consideredforward-looking. Such statements involve known and unknown risks,uncertainties and other factors that may cause actual results, performance orachievements to be materially different from those implied by such statements,and therefore these statements should not be read as guarantees of futureperformance or results. All forward-looking statements are based on Novadaq'scurrent beliefs as well as assumptions made by and information currentlyavailable to Novadaq and relate to, among other things, anticipated financialperformance, business prospects, strategies, regulatory developments, themarket entry (and timing thereof) of additional suppliers of ICG, marketacceptance and future commitments for the PINPOINT endoscopic imaging systemand other Novadaq devices. Readers are cautioned not to place undue relianceon these forward-looking statements, which speak only as of the date of thispress release. Due to risks and uncertainties, including the risks anduncertainties identified by Novadaq in its public securities filings; actualevents may differ materially from current expectations. Novadaq disclaims anyintention or obligation to update or revise any forward-looking statements,whether as a result of new information, future events or otherwise.
SOURCE Novadaq Technologies Inc.
You May Also Like